Factors Influencing Vaginal Fetal Fibronectin Concentrations during Pregnancy

Goffeng, Anette Rossel; Holst, Elisabet; Milsom, Ian; Lindstedt, Göran; Lundberg, Per‐Arne; Andersch, Björn

doi:10.1159/000010068

Cited by 5 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…225,226 To date, fFN testing has been used primarily to rule out PTD in women with preterm labour. 227 Investigators have proposed that fFN may be a marker of infection-related PTD because fFN sensitivity appears greatest for the earliest deliveries (before 32 weeks of gestation), 226 fFN predicts spontaneous but not indicated PTD, 228 and fFN is often 229,230 but not always 65,231 associated with the presence of BV. In addition, exposure of chorion cells in vitro to proinflammatory cytokines and lipopolysacharides stimulates fFN production.…”

Section: Fetal Fibronectin (Ffn)mentioning

confidence: 99%

Pregnancy outcomes and community health: the POUCH study of preterm birth

Holzman¹,

Bullen²,

Fisher

et al. 2001

Paediatric Perinatal Epid

View full text Add to dashboard Cite

In light of the social/ethnic disparity in preterm delivery (PTD) rates, the Pregnancy Outcomes and Community Health (POUCH) Study takes a broad view of the determinants of PTD by attempting to link underlying biological and psychosocial factors. The relationships between placental pathology, maternal biomarkers, and antecedent psychosocial factors are evaluated in three hypothesised pathways of PTD – one characterised primarily by infection, one by maternal vascular disease, and one by premature elevations in corticotropin releasing hormone in the absence of histological evidence of placental pathology. Within each pathway, an emphasis is placed on understanding the roles of stress and of maternal serum alpha‐fetoprotein, an early biomarker associated with PTD. The POUCH Study enrols pregnant women from five Michigan communities. Information about these women and their environments is gathered through detailed interviews and collection of biological samples including hair, urine, saliva, blood, vaginal fluid, and vaginal smear at 15–26 weeks of gestation. We have chosen to focus on the second trimester – a time when pathological processes may have evolved to a detectable stage, but generally before the onset of biological changes that accompany labour. This focus is consistent with the long‐range goal of early detection/intervention and prevention of PTD.

show abstract

Section: Fetal Fibronectin (Ffn)mentioning

confidence: 99%

Pregnancy outcomes and community health: the POUCH study of preterm birth

Holzman¹,

Bullen²,

Fisher

et al. 2001

Paediatric Perinatal Epid

View full text Add to dashboard Cite

show abstract

“…In theory, expression of collagenases or proteases is increased during these infectious processes. The enzymatic activity of these enzymes on the extracellular matrix can lead to the release of fFN [8,10].…”

Section: Introductionmentioning

confidence: 99%